What class of compound is NAD+?

NAD+ is classified as a Pyridine nucleotide cofactor. Within this class, alternative names and analogues include Nicotinamide adenine dinucleotide, β-NAD. The class-level pharmacology shapes both the clinical applications and the safety profile; the longevity / hallmarks of aging literature treats NAD+ alongside its class peers when evaluating relative merits.

How long until I see results from NAD+?

Acute effects from NAD+ appear within hours of dosing for receptor-level changes. healthspan and biological-age endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What is the regulatory status of NAD+?

NAD+ regulatory status: Approved by various routes for various uses; mass-dose IV is off-label in the United States; WADA status not on prohibited list; research level research level investigational. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For healthspan and biological-age use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What are the safety considerations for NAD+?

Flushing common with IV (rate-dependent). Mild GI upset. Pretreatment with niacinamide can reduce flush. For healthspan and biological-age use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. NAD+'s Hours; cellular pool dynamic pharmacokinetic profile and iv/subq/intranasal/oral precursors (nr/nmn) administration route influence the side-effect profile in predictable ways.

Standard cycle for NAD+ is 8–12 weeks of 1x weekly iv; daily subq at lower doses 100-1000 mg dosing via iv/subq/intranasal/oral precursors (nr/nmn), followed by a 4 week complete off-period. The off-period is calibrated to NAD+'s Hours; cellular pool dynamic half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

Home/ Compounds/ NAD+

NAD+

Longevity

For users tracking biological age and healthspan-relevant biomarkers, NAD+ sits within a multi-component longevity framework spanning hallmarks-of-aging from cellular (telomere, senescence, mitochondrial) through integrative (inflammaging, nutrient sensing). The fundamental redox cofactor and substrate for sirtuins and PARPs — declining levels with age are a hallmark of metabolic aging. Cycle-based dosing over 8-12 weeks with pre-post biomarker tracking is the longevity-research convention.

Longevity / Hallmarks of Aging Applications

NAD+ MetabolismCellular ReprogrammingMitochondrial BiogenesisHealthspan ExtensionHallmarks of Aging

Key Takeaways

Longevity lens: NAD+ maps to specific hallmarks-of-aging endpoints rather than to acute clinical markers.
Mechanism: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle.
Healthspan biomarkers: epigenetic age, telomere length, inflammatory markers, metabolic flexibility - all tracked across pre-post cycles.
Longevity protocol: cycle-based 100-1000 mg 1x weekly iv; daily subq at lower doses dosing; 8-12 week cycles favoured over continuous administration.
Longevity stack partners: Epithalon, Thymalin, MOTS-c.

Longevity / Hallmarks of Aging Mechanism

Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Critically, NAD+ is the substrate consumed by sirtuins (SIRT1-7) and PARPs — both depend on adequate NAD+ for their longevity- and DNA-repair-related functions. NAD+ levels decline approximately 50% from age 20 to 60. Healthspan-relevant interpretation of this mechanism asks which biomarkers move, in which direction, on what timescale. The subsections below cover the hallmark mapping, cellular and transcriptional effects, biomarker tracking, and the cycle structure favoured in longevity-research protocols for NAD+.

Mapping to the hallmarks of aging

NAD+'s longevity relevance is best evaluated by mapping its mechanism to the hallmarks-of-aging framework. Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Critically, NAD+ is the substrate consumed by sirtuins (SIRT1-7) and PARPs — both depend on adequate NAD+ for their longevity- and DNA-repair-related functions. NAD+ levels decline approximately 50% from age 20 to 60. This places its dominant contribution in the integrative hallmarks (systemic and inflammatory) layer of the framework, with secondary effects on adjacent hallmarks that combine to produce the broader healthspan-relevant phenotype.

Healthspan markers and biological age

For users measuring epigenetic age, telomere length, or composite biological-age markers (Horvath, PhenoAge, GrimAge) before and after NAD+ cycles, the question is whether the intervention measurably moves these markers. Current evidence varies by compound but the framework for evaluation is shared: paired pre-post measurement with appropriate inter-test interval.

Cellular reprogramming and gene expression

Where NAD+ has measurable effects on transcriptional programmes, the direction of effect tends to be toward younger phenotypes rather than away from them. This signature — partial reversal of age-associated expression changes — is what distinguishes a true longevity-relevant compound from a symptomatic one. The signal strength varies, but the direction is what longevity researchers track.

Longevity / Hallmarks of Aging Applications

Senescence Modulation

NAD+'s contribution to senescence modulation as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.

Inflammaging

Inflammaging maps to one of the hallmarks of aging and is one of the dimensions on which NAD+ is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Mitochondrial Biogenesis

For mitochondrial biogenesis as a longevity-relevant endpoint, NAD+ is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Cellular Reprogramming

NAD+'s contribution to cellular reprogramming as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	IV	100-1000 mg	8–12 weeks on / 4 weeks off
Conservative starter	IV	60-1000 mg	4–6 weeks initial cycle
Longevity focus	IV	100-1000 mg	1x weekly IV; daily SubQ at lower doses
Maintenance phase	IV	70-1000 mg	Ongoing with periodic pauses

Dose timing for NAD+ is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

NAD+ stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from longevity researchers.

NAD+ + Epithalon: Identified by Khavinson in St. Pairs naturally with NAD+'s mechanism in longevity / hallmarks of aging protocols.
NAD+ + Thymalin: Influences T-cell maturation and immune function. Pairs naturally with NAD+'s mechanism in longevity / hallmarks of aging protocols.
NAD+ + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with NAD+'s mechanism in longevity / hallmarks of aging protocols.
NAD+ + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with NAD+'s mechanism in longevity / hallmarks of aging protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Approved by various routes for various uses; mass-dose IV is off-label

Flushing common with IV (rate-dependent). Mild GI upset. Pretreatment with niacinamide can reduce flush.

Lens-specific safety considerations for longevity / hallmarks of aging use of NAD+: Flushing common with IV (rate-dependent). Mild GI upset. Pretreatment with niacinamide can reduce flush. Additional longevity / hallmarks of aging monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

NAD+ metabolism in health and disease

PMID 31738478

Supporting

NAD+ decline with aging and supplementation

PMID 31197173

NAD+ vs Related Peptides

Compound	Profile	Onset	Best For
NAD+	Pyridine nucleotide cofactor	Hours; cellular pool dynamic	Longevity
Epithalon	Pineal-derived tetrapeptide	Very short (minutes)	A pineal-derived tetrapeptide best known for telomerase upregulation and pineal-gland melatonin restoration in long-running rodent and human studies
Thymalin	Thymic polypeptide extract	Variable	A complex of low-molecular-weight thymic polypeptides used in Russian clinical research for decades — immunomodulation, anti-aging, and supportive care in chronic disease
MOTS-c	Mitochondrially-encoded peptide	Hours; tissue-distributed	A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

How do I know if NAD+ is working?

Track outcome metrics that match the compound's primary mechanism: epigenetic age (DNA methylation panels), inflammatory markers (hsCRP, IL-6), metabolic flexibility (HbA1c, fasting insulin, HOMA-IR), body composition (DEXA), and subjective markers (sleep depth, recovery, well-being). Paired pre-post measurement around cycles is the standard framework.

When in life should I start NAD+?

Most longevity-relevant peptides have evidence bases centred on mid-life and later. Earlier use is theoretically reasonable for users with documented age-related markers (elevated inflammation, accelerated epigenetic age) or for compounds whose mechanism is preventative. Below age 35 the benefit for most longevity peptides is theoretical and warrants compound-specific consideration.

Does NAD+ interact with rapamycin, metformin, or other longevity stacks?

Most peptide compounds are compatible with the standard longevity small-molecule stack (rapamycin, metformin, NAD precursors, senolytics in pulsed protocols). Interactions where present are typically additive rather than competitive. Verify case-specifically with a longevity-informed clinician.

What are the long-term safety considerations?

Long-term safety data for most peptide compounds is limited to a small number of well-studied molecules with multi-decade clinical observation. For most others, the long-term framework relies on mechanism-based risk assessment plus accumulating clinical experience. Cycle-based dosing and periodic re-evaluation are appropriate for compounds without 10+ year human safety data.

What is the mechanism of action of NAD+?

Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Critically, NAD+ is the substrate consumed by sirtuins (SIRT1-7) and PARPs — both depend on adequate NAD+ for their longevity- and DNA-repair-related functions. NAD+ levels decline approximately 50% from age 20 to 60. For healthspan and biological-age applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. The longevity / hallmarks of aging interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What route should I use for NAD+?

NAD+ is delivered by iv/subq/intranasal/oral precursors (nr/nmn). The intranasal route is preferred for compounds targeting the central nervous system because it bypasses the BBB via the olfactory pathway. The choice depends on target system and convenience.

Clinical Protocol

Start a NAD+ Protocol

Alukard provides physician-supervised longevity protocols with GMP-certified NAD+ and GMP-certified compounds with biological age testing and healthspan markers.

Get Protocol

Quick Facts

Molecular weight: 663 Da
Half-life: Hours; cellular pool dynamic
WADA: Not on prohibited list
FDA: Approved by various routes for various uses; mass-dose IV is off-label

Stack Partners

Epithalon

Thymalin

MOTS-c

GHK-Cu

Research Note

All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for NAD+ unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised longevity protocols

Start Your Longevity / Hallmarks of Aging Protocol for NAD+

Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised